MALVERN, Pa., March 11, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 562,500 shares of common stock at a public offering price of $8.00 per share, in connection with the company’s recently announced initial public offering of 3,750,000 common shares. The full exercise of the option brings total gross proceeds from the offering to $34,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by the company.
Help employers find you! Check out all the jobs and post your resume.
